Literature DB >> 8921498

A case-control study of risk factors for seropositivity to human T-lymphotropic virus type I (HTLV-I) in Jamaica.

E L Murphy1, R Wilks, B Hanchard, B Cranston, J P Figueroa, W N Gibbs, J Murphy, W A Blattner.   

Abstract

BACKGROUND: We investigated behavioural and environmental risk factors for seropositivity to human T-lymphotropic virus type I (HTLV-I).
METHODS: A nested case-control study of 201 HTLV-I seropositive subjects and 225 age- and sex-matched seronegative controls was performed using questionnaire data from the enrollment visit of a cohort study in 1987-1988. HTLV-I serostatus was confirmed using enzyme-linked immunosorbent assay (ELISA) and Western blot.
RESULTS: Among women, the number of lifetime sexual partners (P < 0.05, chi 2 trend) and the number of different men fathering a child by the woman (P < 0.06, chi 2 trend) were associated with HTLV-I seropositivity. Use by the female subject of an intrauterine device (IUD) was associated with an increased risk of seropositivity (odds ratio (OR) = 2.67, 95% confidence interval (CI): 1.13-6.23); condom use was rare in this population. Among male subjects, a larger number of lifetime sexual partners was also associated with HTLV-I seropositivity (P < 0.05, chi 2 trend). No association was found between HTLV-I seropositivity and educational attainment, income, or occupation. Having been breastfed as a child or receipt of a blood transfusion had elevated but imprecise OR due to very high and low prevalence of the risk factors, respectively. Several variables relating to insect or animal exposure showed no association with HTLV-I seropositivity.
CONCLUSIONS: These data confirm that heterosexual intercourse is a major route of HTLV-I transmission, but do not support suggestions of insect or environmental vectors.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8921498     DOI: 10.1093/ije/25.5.1083

Source DB:  PubMed          Journal:  Int J Epidemiol        ISSN: 0300-5771            Impact factor:   7.196


  14 in total

1.  Quantitative differences in HTLV-I antibody responses: classification and relative risk assessment for asymptomatic carriers and ATL and HAM/TSP patients from Jamaica.

Authors:  Yoshimi Enose-Akahata; Anna Abrams; Kory R Johnson; Elizabeth M Maloney; Steven Jacobson
Journal:  Blood       Date:  2012-02-07       Impact factor: 22.113

2.  Mother-to-Child Transmission of Human T-Cell Lymphotropic Viruses-1/2: What We Know, and What Are the Gaps in Understanding and Preventing This Route of Infection.

Authors:  A B F Carneiro-Proietti; M S Amaranto-Damasio; C F Leal-Horiguchi; R H C Bastos; G Seabra-Freitas; D R Borowiak; M A Ribeiro; F A Proietti; A S D Ferreira; M L Martins
Journal:  J Pediatric Infect Dis Soc       Date:  2014-09       Impact factor: 3.164

Review 3.  Epidemiology, treatment, and prevention of human T-cell leukemia virus type 1-associated diseases.

Authors:  Denise Utsch Gonçalves; Fernando Augusto Proietti; João Gabriel Ramos Ribas; Marcelo Grossi Araújo; Sônia Regina Pinheiro; Antônio Carlos Guedes; Anna Bárbara F Carneiro-Proietti
Journal:  Clin Microbiol Rev       Date:  2010-07       Impact factor: 26.132

4.  Candidate polyanionic microbicides inhibit human T-cell lymphotropic virus type 1 receptor interactions, cell-free infection, and cell-cell spread.

Authors:  Daniela Romer; David W Brighty; Cynthia L Robson; Quentin J Sattentau
Journal:  Antimicrob Agents Chemother       Date:  2008-12-01       Impact factor: 5.191

5.  Humoral immune response to HTLV-1 basic leucine zipper factor (HBZ) in HTLV-1-infected individuals.

Authors:  Yoshimi Enose-Akahata; Anna Abrams; Raya Massoud; Izabela Bialuk; Kory R Johnson; Patrick L Green; Elizabeth M Maloney; Steven Jacobson
Journal:  Retrovirology       Date:  2013-02-13       Impact factor: 4.602

6.  Epidemiology of HTLV-1 in Neyshabour, Northeast of Iran.

Authors:  M R Hedayati-Moghaddam; F Fathimoghadam; I Eftekharzadeh Mashhadi; L Soghandi; H R Bidkhori
Journal:  Iran Red Crescent Med J       Date:  2011-06-01       Impact factor: 0.611

7.  Seroprevalence of human T lymphotropic virus antibodies among healthy blood donors at a tertiary centre in Lagos, Nigeria.

Authors:  Idris Durojaiye; Akinsegun Akinbami; Adedoyin Dosunmu; Sarah Ajibola; Adewumi Adediran; Ebele Uche; Olajumoke Oshinaike; Majeed Odesanya; Akinola Dada; Olaitan Okunoye
Journal:  Pan Afr Med J       Date:  2014-04-21

8.  The prevalence of human T-lymphotropic virus infection among blood donors in southeast China, 2004-2013.

Authors:  Jinzhen Xie; Shengxiang Ge; Yali Zhang; Yongcai Lin; Hongying Ni; Jun Zhang; Changrong Chen
Journal:  PLoS Negl Trop Dis       Date:  2015-04-01

9.  High prevalence of human T-lymphotropic virus infection in indigenous women from the peruvian Amazon.

Authors:  Magaly M Blas; Isaac E Alva; Patricia J García; Cesar Cárcamo; Silvia M Montano; Nicanor Mori; Ricardo Muñante; Joseph R Zunt
Journal:  PLoS One       Date:  2013-09-05       Impact factor: 3.240

10.  Seroprevalence of human T-lymphotropic virus antibodies among patients with lymphoid malignancies at a tertiary center in Lagos, Nigeria.

Authors:  Akinsegun Akinbami; Idris Durojaiye; Adedoyin Dosunmu; Sarah John-Olabode; Adewumi Adediran; Olajumoke Oshinaike; Ebele Uche; Akinola Dada; Mojeed Odesanya; Olaitan Okunoye
Journal:  J Blood Med       Date:  2014-09-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.